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Deregulated expression of genes encoding members of the S100 family of calcium-binding proteins has been associated with the
malignant progression of multiple tumour types. Using a pharmacological expression reactivation approach, we screened 16 S100
genes for evidence of epigenetic regulation in medulloblastoma, the most common malignant brain tumour of childhood. Four family
members (S100A2, S100A4, S100A6 and S100A10) demonstrated evidence of upregulated expression in multiple medulloblastoma
cell lines, following treatment with the DNA methyltransferase inhibitor, 50-aza-20-deoxycytidine. Subsequent analysis revealed
methylation of critical CpG sites located within these four genes in an extended cell line panel. Assessment of these genes in the non-
neoplastic cerebellum (from which medulloblastomas develop) revealed strong somatic methylation affecting S100A2 and S100A4,
whereas S100A6 and S100A10 were unmethylated. Assessed against these normal tissue-specific methylation states, S100A6 and
S100A10 demonstrated tumour-specific hypermethylation in medulloblastoma primary tumours (5 out of 40 and 4 out of 35,
respectively, both 12%) and cell lines (both 7 out of 9, 78%), which was associated with their transcriptional silencing. Moreover,
S100A6 hypermethylation was significantly associated with the aggressive large cell/anaplastic morphophenotype (P¼0.026). In
contrast, pro-metastatic S100A4 displayed evidence of hypomethylation relative to the normal cerebellum in a significant proportion
primary tumours (7 out of 41, 17%) and cell lines (3 out of 9, 33%), which was associated with its elevated expression. In summary,
these data characterise complex patterns of somatic methylation affecting S100 genes in the normal cerebellum and demonstrate
their disruption causing epigenetic deregulation of multiple S100 family members in medulloblastoma development. Epigenetic events
affecting S100 genes have potential clinical utility and merit further investigation as molecular biomarkers for this disease.
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Epigenetic alterations play an important role in the development of
medulloblastoma, an embryonal tumour of the cerebellum, which
accounts for B20% of childhood brain tumours (Giangaspero
et al, 2000; Lindsey et al, 2005). The S100 protein family is a large
family of EF hand calcium-binding proteins of approximately 20
members (Donato, 2003; Marenholz et al, 2004), involved in the
regulation of a variety of cellular processes including cell growth
and cell cycle regulation, differentiation, transcription and
motility. Sixteen members of the gene family (S100A1–S100A16)
map within a 1.65Mb region at chromosome 1q21.3 (Figure 1A)
(Marenholz et al, 2004).
Members of the S100 gene family show divergent patterns of cell
and tissue-specific expression, and the expression of specific
family members is disrupted in a range of diseases including
cancer (Heizmann et al, 2002; Marenholz et al, 2004; Heizmann,
2005). Overexpression of several of the S100 proteins is thought to
be involved in tumour progression, such as S100A4, which is
upregulated in many cancers including medulloblastoma and
promotes angiogenesis and metastasis (Hernan et al, 2003;
Emberley et al, 2004; Helfman et al, 2005; Garrett et al, 2006)
and S100P which is associated with metastasis in breast and
pancreatic cancer (Arumugam et al, 2005; Wang et al, 2006). Other
S100 proteins are downregulated in tumours and have putative
tumour suppressor roles, including S100A2 and S100A6 in prostate
cancer (Rehman et al, 2005).
Expression of several members of the S100 family, including
S100A2, S100A4, S100A6 and S100P, is known to be regulated
epigenetically, by methylation of key CpG sites within the genes or
their promoters (Wicki et al, 1997; Rosty et al, 2002; Sato et al,
2004; Rehman et al, 2005). This regulation has been postulated to
be important in controlling the cell type-specific expression of
S100 genes, as methylation associated with transcriptional silen-
cing of these genes in normal somatic tissues has been found to
occur in a tissue-specific manner (Lesniak et al, 2000; Rosty et al,
2002; Sato et al, 2004). Accordingly, the normal regulation of
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sindividual S100 family members can be disrupted during
tumourigenesis, by aberrant gene-specific methylation events,
which have been demonstrated in diverse cancer types including
lung, prostate, pancreatic and colon cancer (Wicki et al, 1997;
Nakamura and Takenaga, 1998; Lesniak et al, 2000; Feng et al,
2001; Rosty et al, 2002; Rehman et al, 2004, 2005; Sato et al, 2004).
However, the epigenetic status of S100 genes in medulloblastomas
and the normal cerebellum has not been previously investigated.
In this study, we examined 16 members of the S100 gene family
for evidence of methylation-dependent epigenetic regulation in
medulloblastoma, using a pharmacological expression reactivation
approach, involving microarray analysis of gene expression
changes induced by the treatment of medulloblastoma cell lines
with inhibitors of DNA methylation. Four gene family members,
S100A2, S100A4, S100A6 and S100A10, displayed consistent and
confirmed evidence of methylation-dependent upregulation fol-
lowing treatment. The methylation status of these genes was
therefore investigated in detail in medulloblastoma primary
tumours, cell lines and the normal cerebellum, to identify and
characterise any epigenetic events affecting them, and to assess any
potential biological roles and/or clinicopathological significance in
medulloblastoma pathogenesis.
MATERIALS AND METHODS
Cell lines
Nine independently derived medulloblastoma cell lines (DAOY,
D283 Med, MHH-MED-1, MEB-MED8A, D341 Med, D384 Med,
D425 Med, D556 Med and UW228-3) were studied. All cells were
grown under recommended culture conditions provided by
suppliers (see acknowledgements) and cell line identity was
confirmed before use by karyotyping (data not shown). Cell line
DNA was extracted using the Qiagen DNeasy kit (Qiagen, Crawley,
UK).
Primary tumours and normal control samples
A cohort of 41 primary medulloblastomas was analysed including
representatives of all the major histopathological subtypes (25
classic, six large cell/anaplastic and 10 nodular/desmoplastic)
(Giangaspero et al, 2000). Patients (15 females and 26 males) ranged
in age from 1.3 to 19 years (seven infants o3 years, 30 children 3–
16 years and four adults 416 years). Six cerebellar samples were
analysed consisting of post-mortem material from three fetuses
(18- 19- and 22-weeks gestational age), one infant (newborn) and
two adults (60 and 67 years) who had died of non-neoplastic
conditions. DNA was extracted from frozen tissues using standard
methods and from formalin-fixed, paraffin-embedded tissue using
a Nucleon hard tissue kit (Amersham Biosciences, Little Chalfont,
UK). Local Ethical Committee and Institutional Review Board
approval was obtained for the collection, storage and biological
study of all material.
50-Aza-20-deoxycytidine (5-aza CdR) treatment
Four cell lines (DAOY, D283 Med, D425 Med and MEB-MED8A)
were grown in the presence or absence of the demethylating agent
5-aza CdR (5mM) (Sigma-Aldrich, Poole, UK) for 3 days. Medium
was renewed daily.
Microarray analysis
Total RNA was extracted from cell lines D283 Med, D425 Med and
MEB-MED8A, which had been grown in parallel cultures with or
without 5-aza CdR treatment. These cell lines were selected
for analysis as they exhibit characteristic chromosomal defects
representative of primary medulloblastomas (Langdon et al, 2006).
RNA was extracted from 10
7 cells using Trizol reagent (Invitrogen,
Paisley, UK) according to manufacturer’s instructions. Microarray
expression analysis was performed at the Newcastle University
microarray facility; RNA was converted into biotin-labelled cRNA
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Figure 1 Methylation-dependent regulation of S100 genes in medulloblastoma. (A) The S100 gene cluster at 1q21.3, showing the position (vertical lines)
and direction of transcription (4, o) of each gene. Physical positions are based on NCBI Assembly 36 of the human genome (see http://
www.ncbi.nlm.nih.gov/). Genes not belonging to the S100 family have been omitted for clarity. (B) Methylation-dependent changes in expression of 16 S100
genes in three medulloblastoma cell lines (MEB-MED8A, D283Med, D425Med), following treatment with the DNA methyltransferase inhibitor, 5-aza-CdR
(5mM, 72h), determined by analysis using the Affymetrix U133A Human expression array (sequence identities of probes indicated were verified
independently). Fold-changes in expression detected by each probe are shown, based on signal intensities assessed by MAS5 software (Affymetrix). Four
genes (marked**) displayed evidence of positive methylation-dependent regulation in X2 cell lines; S100A2, S100A4, S100A6 and S100A10.
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manufacturer’s protocols (Affymetrix, Santa Clara, CA, USA).
MAS5 software (Affymetrix) was used for data processing,
normalisation and calculation of signal intensities. Signal inten-
sities were compared between treatment conditions using Micro-
soft Excel software (Microsoft, Reading, UK).
Analysis of S100 gene methylation status
Bisulphite treatment of DNA was carried out using a CpG genome
DNA modification kit (Serologicals, Livingston, UK) according to
the manufacturer’s instructions. The promoter and exon1 regions
of S100A2 and S100A6 and a region within the first intron of
S100A4 were amplified following bisulphite treatment using
previously published primers and conditions (Rosty et al, 2002;
Rehman et al, 2005). The promoter region of S100A10 (Huang
et al, 2003) was analysed using primers designed by ‘MethPrimer’
(Li and Dahiya, 2002) to amplify a region of the CpG island 400–
652bp relative to the transcriptional start site. Primer sequences
were S100A10F 50-ATTATTTGTTGGATGATTTTGTAGG-30 and
S100A10R 50-ACACAAAAAAATAAATCCCCTATTC-30 (designed
to amplify the antisense strand following bisulphite conversion).
Thirty nanograms of bisulphite treated DNA was used per
reaction. PCR products were amplified using standard conditions
with an annealing temperature of 601C. PCR products were directly
sequenced with a CEQ DTCS kit (Beckman Coulter, High
Wycombe, UK). Sequenced products were analysed on a CEQ
2000XL DNA analysis system (Beckman Coulter), and the
methylation status at each CpG residue determined by assessment
of the relative peak intensities.
Combined bisulphite and restriction analysis (COBRA (Xiong
and Laird, 1997) of S100A4 was carried out by overnight digestion
of the 142bp PCR product at 371C with the HypCH4IV restriction
endonuclease (New England Biolabs, Hitchin, UK), which has the
recognition sequence 50-ACGT-30 and which cuts twice within the
product if fully methylated before bisulphite conversion to give
100, 26 and 16bp fragments. Digested PCR products were
separated on a 4% Nusieve 3:1 agarose gel in 1 TBE (0.09 M
Tris-Borate, 0.002 M EDTA pH 9) and stained with ethidium
bromide, before visualisation by transillumination under ultra-
violet (UV) light. The unmethylated control for COBRA and
bisulphite sequence analysis consisted of a pool of 20 newborn
cord blood DNAs, the methylated control was universal methylated
DNA (Serologicals Corporation, Livingston, UK). Representative
examples of PCR products showing different digestion patterns
were sequenced as described above, to determine relative peak
intensities.
Reverse transcription PCR (RT–PCR)
RNA was extracted from 10
7 subconfluent cells using Trizol
reagent (Invitrogen, Paisley, UK) according to manufacturer’s
instructions. One microgram of total RNA was used to synthesise
cDNA using a reverse transcription system (Promega, South-
ampton, UK). Equivalent amounts of this cDNA were used for PCR
amplification of the respective S100 gene, RASSF1A and ACTB
transcripts. RT–PCRs for S100A2, S100A4 and S100A6 were
carried out using previously published primers and conditions
(Rosty et al, 2002; Rehman et al, 2005). RT primers for S100A10
were designed using transcript information obtained from the
Ensembl genome browser (www.ensembl.org; Gene ID,
ENSG00000197747). Primer sequences were S100A10rtF (in exon
2) 50-TTCACAAATTCGCTGGGGATAA-30 and S100A10rtR (in
exon 3) 50-AACTGCTCATTTCTGCCTACTTCT, which amplified
a 264bp product. PCR products were amplified using standard
conditions with an annealing temperature of 541C. RT–PCR of
RASSF1A was used as a positive control and was carried out
according to procedures published previously (Lusher et al, 2002).
RT–PCR of ACTB (encoding b-actin, a housekeeping gene) was
used as a control for RNA concentration and integrity and was
carried out using previously published primers and conditions
(Horikoshi et al, 1992). PCR products were electrophoresed on a
2% agarose gel in 1 TBE and stained with ethidium bromide,
before visualisation by transillumination under UV light.
RESULTS
Re-expression of S100 family members following
demethylating treatment of medulloblastoma cell lines:
identification of candidate epigenetically regulated genes
To identify S100 genes showing evidence of methylation-
dependent transcriptional regulation in medulloblastoma, three
medulloblastoma cell lines (D425Med, D283Med and MEB-
MED8A) were cultured in the presence or absence of the demethylat-
ing agent, 5-aza CdR. Resultant expression changes were assessed
using the Affymetrix Human U133A array. The U133A array
contains probe sets which recognise 16 S100 genes (S100A1-
S100A14, S100b and S100P), for which probe sequence identity and
specificity could be verified using the BLAST sequence alignment
tool (http://www.ncbi.nlm.nih.gov/BLAST/). Changes in probe
signal intensity following 5-aza CdR treatment were calculated
and genes showing an expression increase 42-fold were classed
as being significantly upregulated, and thus showing evidence of
methylation-dependent transcriptional regulation. Four indepen-
dent S100 transcripts showed evidence of transcriptional upregu-
lation in multiple cell lines (Figure 1B); S100A6 and S100A10 were
upregulated in all three cell lines, while S100A2 and S100A4 were
upregulated in two cell lines. In addition, S100A3, S100A11 and
S100P were each upregulated in one cell line, and the remaining
S100 genes were not significantly upregulated in any cell line.
The expression changes observed for S100A6, S100A10, S100A2
and S100A4 on array analysis were next validated in an
independent series of experiments by RT–PCR (Figure 2A). The
increases in expression observed by microarray for these genes
following 5-aza CdR treatment were also clearly seen using RT–
PCR methods, with good concordance between results obtained
using the two techniques (Figure 2A). Reverse transcription–PCR
analysis following demethylation treatment was also extended to a
fourth medulloblastoma cell line, DAOY, which did not appear to
show altered expression of any of the four S100 genes examined
following 5-aza CdR treatment, despite clear evidence of re-
expression of the RASSF1A control transcript.
The methylation status of S100A2, S100A4, S100A6 and
S100A10 in medulloblastoma cell lines is associated with
methylation-dependent transcriptional silencing
S100 genes with confirmed evidence of methylation-dependent
upregulation in X2 medulloblastoma cell lines were selected for
direct analysis of their DNA methylation status. The methylation
status of CpG sites within the promoter/exon 1 regions of S100A6
and S100A2, which have previously been identified as being
involved in their epigenetic regulation (Rehman et al, 2005), was
established in a panel of nine medulloblastoma cell lines by
bisulphite sequencing. Both genes were frequently methylated (in 7
out of 9 and 8 out of 9 lines, respectively). S100A6 displayed
extensive methylation in D283 Med, D425 Med, MEB-MED8A,
MHH-MED-1, D341 Med, D384 Med and D556 Med; the
methylation of S100A6 in D283 Med, D425 Med, MEB-MED8A is
in accordance with its observed methylation-dependent transcrip-
tional silencing and re-activation by 5-aza CdR in these cell lines.
In contrast, DAOY and UW228-3 were completely unmethylated,
correlating with the higher level of expression and the lack of
expression change following demethylating treatment, seen in
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sDAOY (Figure 2A and D). S100A2 showed more variable
methylation patterns, with methylation ranging from partial
methylation at one site (DAOY) to complete methylation at all
sites (D283 Med) (Figure 2D). However, the observed methylation
patterns again correlated well with methylation-dependent tran-
scriptional silencing (Figure 2A and D), except in the case of D425
Med, which is densely methylated and transcriptionally silenced,
but does not undergo significant re-expression following 5 aza CdR
treatment, suggesting that methylation-independent mechanisms
are involved in its silencing.
Methylation analysis of S100A10 has not been performed
previously; however, the promoter and associated CpG island
have been characterised. (Huang et al, 2003) Primers were
designed using MethPrimer (Li and Dahiya, 2002) to assess the
methylation status of a region of the S100A10 promoter-associated
CpG island (400–652bp relative to the transcriptional start) site by
bisulphite sequencing (see Figure 2B and D). This region was
methylated at multiple CpG residues in 7 out of 9 cell lines,
including all three cell lines, which showed evidence of transcrip-
tional silencing and methylation-dependent upregulation of
S100A10 following treatment with 5-aza CdR (D283 Med, D425
Med, MEB-MED8A), but was not methylated in DAOY, which
showed higher endogenous expression levels and no clear change
in expression following demethylating treatment (Figure 2A),
indicating that methylation of this region is involved in the
transcriptional silencing and epigenetic regulation of S100A10.
S100A4 does not contain a promoter-associated CpG island, but
has been shown to be epigenetically regulated by methylation of
critical intragenic CpG sites (Rosty et al, 2002). We therefore
assessed the methylation status of two CpG sites within its first
intron, whose methylation has been previously correlated with
expression (Rosty et al, 2002). Methylation was assessed by
COBRA (Figure 1C), with representative examples (n¼3) of each
digestion pattern confirmed by bisulphite sequencing. These two
CpG sites were fully methylated in 6 out of 9 cell lines, and their
methylation status correlated well with the expression patterns
observed; reduced expression and 5-aza CdR-associated upregula-
tion was seen in methylated cell lines (D283 Med, D425 Med), but
not in unmethylated cell lines (MEB-MED8A, DAOY) (Figure 1;
Figure 2A and D). These data were reinforced by extension of RT–
PCR expression analysis of S100A4 to two further cell lines (MHH-
MED1, D556 Med), which produced the anticipated expression
patterns; unmethylated MHH-MED1 showed higher endogenous
expression and no evidence of methylation-dependent regulation,
whereas the methylated D556 Med cell line displayed transcrip-
tional silencing and methylation-dependent upregulation following
5-aza CdR treatment (data not shown).
Methylation status of S100 genes in the normal cerebellum
Gene-specific methylation can be a feature of normal somatic
tissues (Strathdee et al, 2004). It is therefore crucial to establish the
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Figure 2 Epigenetic inactivation of S100 genes by promoter hypermethylation in medulloblastoma cell lines. (A) Expression analysis of S100 genes in
medulloblastoma cell lines. RT–PCR analysis of S100A2, S100A4, S100A6 and S100A10 is shown for cell lines grown in the presence (þ) or absence ( )o f
the demethylating agent 5-aza CdR (5mM, 72h). Probe signal intensities generated for each gene in independent microarray experiments (see Figure 1A) are
also given for comparison. RASSF1A (positive methylation-regulated gene) and ACTB (housekeeping) controls are also shown. (B) Representative examples
of bisulphite sequence analysis. Two electropherograms showing analysis of three CpG sites within the S100A10 promoter from a highly methylated cell line
(D384) and an unmethylated cell line (DAOY). Individual CpG sites are underlined. (C) Representative examples of COBRA analysis of S100A4. PCR
products from bisulphite-treated cell line DNA were digested with HpyCH4IV, which cuts the product twice when CpG sites are methylated, generating
products of 100bp (shown) and 26 and 16bp (not shown). Unmethylated control (U) was normal blood DNA, methylated control (M) was universal
methylated DNA (Serologicals Corporation, Livingston, UK). (D) Methylation status analysis of CpG residues within the promoter-associated CpG islands of
S100A2, S100A6 and S100A10 and first intron of S100A4 in nine medulloblastoma cell lines, determined by bisulphite sequencing and estimation of relative
peak heights. S100A4 PCR products representative of different digestion patterns were sequenced and used to assign methylation levels to samples showing
equivalent digestion patterns. Filled circles, 475% methylation; half-filled circles, 25–75% methylation; empty circles, o25% methylation; NA, not analysed.
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tissues before any role for aberrant methylation patterns in
tumourigenesis can be assessed. Six normal cerebellar samples,
comprising fetal, infant and adult examples were therefore
assessed for the methylation status of all four S100 genes under
investigation (Figure 3). For S100A4, S100A6 and S100A10,
consistent methylation patterns were observed across all samples.
S100A6 and S100A10 were somatically unmethylated, with no
evidence of methylation of either promoter-associated CpG island
observed, with the exception of one sample which showed minimal
methylation (o25%) at 2 out of 13 sites in the S100A10 CpG
island. In contrast, S100A4 was somatically methylated, showing
evidence of high-level methylation at both CpG residues assessed
in all normal cerebellar samples. S100A2 also showed evidence of
methylation in the normal cerebellum, although the methylation
patterns detected were variable between samples, both in terms of
the number of methylated CpG residues and the extent of
methylation observed at these residues.
Aberrant methylation patterns identify roles for S100
genes in medulloblastoma pathogenesis
S100 gene methylation patterns were next investigated in a series of
primary medulloblastomas, and, together with patterns previously
observed for medulloblastoma cell lines (Figure 2), were assessed
against the normal methylation patterns observed for each gene in
the cerebellum, for evidence of altered methylation states. In the
majority of cases, methylation patterns observed in medulloblas-
tomas corresponded to the methylation status of the normal
cerebellum (Figure 3). For S100A6 and S100A10, the majority of
medulloblastomas were unmethylated (35 out of 40 and 31 out of
35 of analysable samples, 87.5 and 88.5% respectively); however
five tumours (12.5%) and seven cell lines (78%) showed evidence
of hypermethylation of the S100A6 promoter relative to the normal
cerebellum. S100A10 was hypermethylated in four tumours
(11.4%) and seven cell lines (78%), relative to the normal
cerebellum. Direct analysis of expression in tumours was not
possible, as RNA was not available for the majority of the cohort;
however, the hypermethylation of S100A10 observed in primary
tumours is of a comparable level to that seen in the cell lines,
consistent with its epigenetic transcriptional inactivation and
candidate tumour suppressor role in disease pathogenesis (Figures
2A, D and 3). The hypermethylation observed for S100A6 was less
pronounced in primary tumours (affecting a limited number of
CpG residues) than cell lines and further work is needed to
determine whether this level of methylation leads to transcrip-
tional silencing.
In contrast, all medulloblastomas showed some evidence of
methylation of the CpG regions assessed in S100A4 and S100A2.
Whereas the normal cerebellum and the majority of primary
medulloblastomas (34 out of 41) and medulloblastoma cell lines (6
out of 9) demonstrated complete methylation (475%) of the
S100A4 intronic CpG sites analysed, a subset of primary tumours
(17%; 7 out of 41) and cell lines (33%; 3 out of 9) were
undermethylated in comparison, displaying either partial methyla-
tion or no evidence of methylation at each site (Figures 2D and 3).
Considered alongside the methylation-dependent transcriptional
silencing observed for S100A4 in medulloblastoma cell lines
(Figure 2A), these findings support (i) the somatic hypermethyla-
tion-associated transcriptional silencing of S100A4 in the normal
cerebellum, and (ii) tumour-specific hypomethylation of S100A4 in
a subset of medulloblastomas, consistent with elevated expression
and a pro-tumourigenic role.
Patterns of methylation observed for S100A2 were complex;
evidence of methylation was observed in all primary tumours
tested; however, considerable variation was seen in both the
number of CpG residues affected and the extent of methylation
observed at individual CpG residues (Figure 3). A comparable
incidence and variability of patterns of methylation were also
detected in medulloblastoma cell lines and the normal cerebellum,
and our data do not therefore provide any clear evidence to
indicate the existence of aberrant tumour-specific patterns of
S100A2 methylation in medulloblastomas (Figures 2D and 3). In
view of the methylation-dependent transcriptional silencing
associated with a range of S100A2 methylation states in
medulloblastoma cell lines (Figure 2A and D), our data suggest
that S100A2 methylation in the normal cerebellum is associated
with its somatic epigenetic transcriptional silencing, but more
detailed investigations are now required to explore any role for the
epigenetic deregulation of S100A2 in medulloblastoma.
Clinicopathological significance of S100 methylation
events in medulloblastomas
Tumour-specific methylation patterns detected for the S100A4,
S100A6 and S100A10 genes were next assessed against basic
S100A2 S100A4 S100A6 S100A10
CpG residue
Normal
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tumours
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1
1
1
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79
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Figure 3 Methylation status of S100 genes in primary medulloblastomas and the normal cerebellum. Analysis of methylation at CpG residues within the
promoter-associated CpG islands of S100A2, S100A6 and S100A10 and the first intron of S100A4, is shown in normal cerebella and selected
medulloblastoma primary tumours, determined by bisulphite sequencing and estimation of relative peak heights (as described in Figure 2). Filled circles,
475% methylation; half-filled circles, 25–75% methylation; empty circles, o25% methylation.
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(age, sex, histopathological subtype), to make a preliminary
assessment of any clinicopathological significance in disease
development. S100A6 methylation showed a statistically significant
association with the large cell/anaplastic histopathological morpho-
phenotype (50%; (3 out of 6) of large cell/anaplastic tumours vs 8%
(2 out of 25) of classic and 0% (0 out of 9) of nodular/desmoplastic
tumours; P¼0.026 by Fisher’s exact test). No further significant
associations were found for any gene.
DISCUSSION
This study demonstrates a role for the epigenetic deregulation of
three members of the S100 gene family, S100A4, S100A6 and
S100A10, in medulloblastoma tumourigenesis. Furthermore, our
data provide evidence for the control of S100 gene expression in
the normal cerebellum by gene-specific somatic methylation
events, and highlight the importance of assessing epigenetic events
in tumour development in the context of normal tissue-specific
methylation patterns.
Epigenetic deregulation of gene expression plays an important
role in the development of medulloblastoma, and studies of DNA
methylation have identified a series of putative tumour suppressor
genes for this disease; however, analysis has so far been restricted
to a limited number of candidate genes (Lindsey et al, 2005). In
this study, we therefore used a pharmacological expression
reactivation approach, to allow a more global analysis of gene
expression changes using expression microarrays. Using this
analysis to assess members of the S100 gene family for evidence
of methylation-dependent regulation, we have successfully identi-
fied four S100 family members which showed upregulation in
multiple cell lines following demethylation treatment, and were
subsequently shown to be associated with specific DNA methyla-
tion events. Our findings thus strongly support the value of this
experimental approach for the identification of novel methylated
genes relevant to both normal development and oncogenesis, and
provide important precedent for the epigenetic deregulation of
S100 gene expression in medulloblastoma. Moreover, the role of
methylation events in the regulation of S100 gene expression in the
normal and malignant cerebellum may yet be more extensive than
recognised currently. Our investigations of S100 gene DNA
methylation status were limited to four genes that displayed
evidence of methylation-dependent regulation in multiple cell
lines. Additional S100 genes either (i) showed evidence of
methylation-dependent regulation in a more limited number of
cell lines (o2; S100A3, S100A11, S100P and S100G), and were
therefore not investigated further in the present study, or (ii) were
not represented on the U133A expression microarray (e.g.,
S100A15), suggesting that more systematic investigations are
now required to investigate any roles for DNA methylation events
in the epigenetic regulation of further S100 family members in
medulloblastoma.
Two of the genes identified by this approach, S100A6 and
S100A10, were each hypermethylated in a proportion of both
medulloblastoma cell lines and primary tumours (each in B12%
of cases), but not in the normal cerebellum. The higher frequency
of hypermethylation observed for both genes in cell lines than
tumours may reflect either a limited representation of the clinical
and pathological diversity of primary medulloblastomas by these
cell lines (Langdon et al, 2006), or an involvement of culture-
related de novo methylation events (Jones et al, 1990; Pantoja et al,
2005). Nonetheless, for both genes a significant frequency of
tumour-specific methylation was observed in primary tumours,
which was associated with transcriptional silencing in medullo-
blastoma cell lines, indicating epigenetic inactivation and candi-
date tumour suppressor roles for S100A6 and S100A10 in primary
medulloblastoma development. S100A6 has been shown to be
expressed in a cell type-specific manner in the brain, with
expression present in subsets of neurons including granule cells
of the cerebellum (Filipek et al, 1993). Consistent with this
observation, the S100A6 promoter was unmethylated in the normal
cerebellum in the present study. In other tumour types, S100A6 has
also been reported to be hypermethylated in prostate cancer
(Rehman et al, 2005). S100A10 is also expressed in the brain
(Zimmer et al, 2005). To our knowledge, the present study is the
first to demonstrate that S100A10 expression can be deregulated by
methylation of its promoter-associated CpG island in tumourigen-
esis. The finding that S100A10 was hypermethylated in medullo-
blastoma cell lines and tumours was unexpected, as its
overexpression has previously been associated with plasminogen-
dependent cellular invasiveness in fibrosarcoma and colorectal
cancer cells (Choi et al, 2003; Zhang et al, 2004). However, S100A10
can interact with a variety of proteins and is involved in diverse
processes (reviewed in Santamaria-Kisiel et al, 2006), and studies
to clarify its role in medulloblastoma tumourigenesis are now
required.
In contrast, we have demonstrated consistent evidence of
methylation of S100A2 and S100A4 in the normal cerebellum.
The methylation patterns observed for both genes are comparable
to those associated with transcriptional silencing in medullo-
blastoma cell lines, suggesting that expression of these genes is
reduced or silenced epigenetically in the normal non-neoplastic
cerebellum. There is growing evidence that a number of genes are
epigenetically silenced by somatic methylation in normal tissues
(reviewed in Strathdee et al, 2004). Previously we have shown
evidence of partial methylation of CASP8, HIC1 and EDNRB
(Lindsey et al, 2004) in non-neoplastic cerebella. As less than 50
genes have been analysed for methylation in medulloblastoma
and the normal cerebellum (Lindsey et al, 2005); this raises
the possibility that somatic methylation in the normal cerebellum
may be a feature of a significant number of genes, although for
some it may be restricted to specific cell types within the
cerebellum. In addition to cell type-specific methylation
(Lesniak et al, 2000; Rosty et al, 2002; Sato et al, 2004), members
of the S100 gene family have been shown to undergo temporal
methylation changes during development, for example S100b,
becomes demethylated during astrocyte development in the
mouse brain correlating with the time when its expression
commences at E14 (Namihira et al, 2004). This raises the
possibility that aberrant methylation in embryonal tumours such
as medulloblastoma may reflect a failure of developmentally
regulated methylation changes. The identification of normal
tissue-specific methylation in the non-neoplastic cerebellum
emphasizes the importance of including relevant somatic tissue
controls in medulloblastoma methylation studies (Lindsey et al,
2004; Lindsey et al, 2005).
S100A4 showed complete methylation of the intronic CpG sites
analysed in all normal cerebellar samples, consistent with its
epigenetic transcriptional silencing (see above). S100A4 has been
previously shown to be methylated in other normal tissues,
including pancreatic tissue (Rosty et al, 2002). Three medullo-
blastoma cell lines were unmethylated for S100A4, and were
associated with higher gene expression unaffected by demethyla-
tion treatment (in contrast to methylated lines, which were
associated with methylation-dependent transcriptional silencing),
suggesting that they had undergone selection for hypomethylation
and overexpression of S100A4 during the tumourigenic process.
No tumour samples were completely unmethylated at S100A4;
however, 7 out of 41 (17%) of tumours displayed reduced levels of
methylation compared to the normal cerebellum. S100A4 hypo-
methylation is also a feature of other cancers, including pancreatic
and colon adenocarcinoma (Nakamura and Takenaga, 1998; Rosty
et al, 2002). S100A4 promotes angiogenesis and extracellular
matrix degradation through its upregulation of specific matrix
metalloproteases (reviewed in Helfman et al, 2005) and high levels
Epigenetic deregulation of S100 genes in medulloblastoma
JC Lindsey et al
272
British Journal of Cancer (2007) 97(2), 267–274 & 2007 Cancer Research UK
G
e
n
e
t
i
c
s
a
n
d
G
e
n
o
m
i
c
sof S100A4 expression are associated with metastatic progression in
a wide range of cancers including medulloblastoma (Hernan et al,
2003). Current findings are therefore consistent with a role for the
oncogenic activation of S100A4 by hypomethylation-associated
expression upregulation in medulloblastoma tumourigenesis.
S100A2 has been postulated in certain studies to play a
suppressor role in tumour development, as it shows reduced
expression in a range of cancer types, while other investigators
have been unable to show any clear difference in methylation
patterns between tumours and normal tissue (Rehman et al,
2005). S100A2 methylation was detected in all normal cerebella,
cell line and tumour samples tested; however, significant
variability in methylation patterns and levels were observed in
all sample groups. While these methylation patterns were
associated with transcriptional silencing in medulloblastoma cell
lines, suggesting that S100A2 is epigenetically silenced by
hypermethylation in the normal cerebellum, no clear evidence of
aberrant tumour-specific epigenetic regulation in medulloblastoma
development was found, and more detailed examination of
extended tumour cohorts are now required to further discern
any role in medulloblastoma.
The majority of the S100 genes, including S100A2, S100A4,
S100A6 and S100A10 are organised in a cluster on chromosome
1q21.3 (Figure 1). Recent studies have provided precedent for
epigenetic silencing across an entire chromosome band in
colorectal cancer (Frigola et al, 2006); however, this does not
appear to be the case for the S100 gene cluster in medulloblastoma.
Microarray analysis of S100 gene expression changes following
demethylation treatment of medulloblastoma cell lines (Figure 1)
shows that there is no positional clustering of upregulated genes
and the expression of many genes in the cluster remains
unchanged. Furthermore, analysis of DNA methylation changes
shows that some medulloblastoma cell lines (e.g., MHH-MED1,
MEB-MED8A) show both hypermethylation (e.g., of S100A6) and
hypomethylation (e.g., of S100A4) of genes in close physical
proximity, suggesting that epigenetic remodelling appears to be
localised within the S100 cluster, involving gene-specific hyper-
methylation and hypomethylation events. Furthermore, our
findings indicate that S100 gene methylation patterns may have
clinical significance and potential utility as medulloblastoma
biomarkers. Based on an initial analysis in our limited cohort,
methylation of S100A6 was significantly associated with the
more aggressive large cell/anaplastic histopathological variant
(Giangaspero et al, 2000; McManamy et al, 2003), and investiga-
tions in large uniformly treated clinical trials cohorts are now
required to investigate these relationships further.
A proportion of the CpG methylation found in normal tissue
contributes to the silencing of transposable elements and foreign
DNA sequences and the cancer genome is known to be globally
hypomethylated at these sites, which contributes towards its
overall genomic instability (Ehrlich, 2002). However, the role of
methylation in the control of expression of individual genes in
normal tissues has not been studied in detail and the majority of
studies of the methylation status of individual genes in tumours
have focused on hypermethylation events leading to the epigenetic
inactivation of putative tumour suppressor genes. This has led to
the advocation of demethylating agents as anti-cancer therapeutics
(reviewed in Strathdee and Brown, 2002). The growing evidence
that a number of genes are epigenetically silenced by methylation
in normal tissues (reviewed in Strathdee et al, 2004) and that some
of these genes such as S100A4 may be tumour promoting, now
forces a reconsideration of our understanding of how alterations in
the epigenome contribute to cancer development, and the rationale
and mechanisms underlying the therapeutic efficacy of such
‘epigenetic’ therapies.
The epigenetic regulation of the S100 gene family in medullo-
blastoma and the normal cerebellum illustrates the complex nature
of the epigenome, with different family members being subject to
both tissue and tumour-specific epigenetic control by DNA
methylation, involving both hypomethylation and hypermethyla-
tion events which occur during tumourigenesis. Further work is
now needed to (i) understand the role of S100 gene family
deregulation in medulloblastoma development and (ii) determine
the relative contribution of hypo and hypermethylation events in
the development of this tumour and its implications for cancer
therapeutics.
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